U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review
- ByBenzinga-
The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept)...